Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 23:22:64-66.
doi: 10.1016/j.rmcr.2017.06.013. eCollection 2017.

"Liquid elbows" due to afatinib administration

Paul Zarogoulidis  1 , Panos Chinelis  1 , Anastasia Athanasiadou  1 , Konstantinos Porpodis  1 , Anastasios Kallianos  2 , Aggeliki Rapti  3 , Georgia Trakada  2 , Lemonia Velentza  2 , Haidong Huang  4 , Theodora Tsiouda  5 , Wolfgang Hohenforst-Schmidt  6
Affiliations
Case Reports

"Liquid elbows" due to afatinib administration

Paul Zarogoulidis et al. Respir Med Case Rep. .

Abstract

Non-small cell lung cancer adenocarcinoma in the past decade has targeted therapies as the cornerstone for therapy. In specific patients with epidermal growth factor receptor mutation have three different therapy approaches with the tyrosine kinase inhibitors: erlotinib, gefitinib and afatinib. Nowadays we can use tyrosine kinase inhibitors as second line treatment for squamous cell carcinoma. We present a case with a patient with squamous cell carcinoma receiving afatinib tyrosine kinase inhibitor who presented elbow bursitis or olecranon bursitis in both elbows.

Keywords: Afatinib; Elbow bursitis; Olecranon bursitis; Tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pet-CT upon disease relapse.
Fig. 2
Fig. 2
Endoscopy performed by Paul Zarogoulidis with a Pentax EB-1970UK EBUS system after Pet-CT.
Fig. 3
Fig. 3
Left elbow after surgery for elbow bursitis or olecranon bursitis.
Fig. 4
Fig. 4
Elbow bursitis or olecranon bursitis of the right hand.
Fig. 5
Fig. 5
Both hands.
Fig. 6
Fig. 6
Presence of inflammatory cells (lymphocytes, plasma cells, neutrophils) and foci of hemorrhage.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.
    Zarogoulidis P, Huang H, Tsiouda T, Sardeli C, Trakada G, Veletza L, Kallianos A, Kosmidis C, Rapti A, Papaemmanouil L, Hatzibougias D, Drougas D, Bai C, Hohenforst-Schmidt W. Zarogoulidis P, et al. Respir Med Case Rep. 2017 Oct 26;22:283-286. doi: 10.1016/j.rmcr.2017.10.006. eCollection 2017. Respir Med Case Rep. 2017. PMID: 29124007 Free PMC article.
  • Inhaled Cisplatin for NSCLC: Facts and Results.
    Kosmidis C, Sapalidis K, Zarogoulidis P, Sardeli C, Koulouris C, Giannakidis D, Pavlidis E, Katsaounis A, Michalopoulos N, Mantalobas S, Koimtzis G, Alexandrou V, Tsiouda T, Amaniti A, Kesisoglou I. Kosmidis C, et al. Int J Mol Sci. 2019 Apr 24;20(8):2005. doi: 10.3390/ijms20082005. Int J Mol Sci. 2019. PMID: 31022839 Free PMC article. Review.
  • Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer.
    Tsiouda T, Sardeli C, Porpodis K, Pilikidou M, Apostolidis G, Kyrka K, Miziou A, Kyrka K, Tsingerlioti Z, Papadopoulou S, Heva A, Koulouris C, Giannakidis D, Boniou K, Kesisoglou I, Vagionas A, Kosmidis C, Sevva C, Papazisis G, Goganau AM, Sapalidis K, Tsakiridis K, Tryfon S, Platanas M, Baka S, Zaric B, Perin B, Petanidis S, Zarogoulidis P. Tsiouda T, et al. J Cancer. 2020 Mar 5;11(11):3407-3415. doi: 10.7150/jca.40196. eCollection 2020. J Cancer. 2020. PMID: 32231747 Free PMC article.
  • Inhaled chemotherapy adverse effects: mechanisms and protection methods.
    Sardeli C, Zarogoulidis P, Kosmidis C, Amaniti A, Katsaounis A, Giannakidis D, Koulouris C, Hohenforst-Schmidt W, Huang H, Bai C, Michalopoulos N, Tsakiridis K, Romanidis K, Oikonomou P, Mponiou K, Vagionas A, Goganau AM, Kesisoglou I, Sapalidis K. Sardeli C, et al. Lung Cancer Manag. 2020 Jan 16;8(4):LMT19. doi: 10.2217/lmt-2019-0007. Lung Cancer Manag. 2020. PMID: 31983927 Free PMC article. Review.
  • Psoriatic arthritis due to nivolumab administration a case report and review of the literature.
    Sapalidis K, Kosmidis C, Michalopoulos N, Koulouris C, Mantalobas S, Giannakidis D, Munteanu A, Surlin V, Laskou S, Zarogoulidis P, Drougas D, Sardeli C, Karapantzou C, Karapantzos I, Hohenforst-Schmidt W, Huang H, Kesisoglou I. Sapalidis K, et al. Respir Med Case Rep. 2018 Mar 2;23:182-187. doi: 10.1016/j.rmcr.2018.03.001. eCollection 2018. Respir Med Case Rep. 2018. PMID: 29719813 Free PMC article.

References

    1. Zarogoulidis K., Zarogoulidis P., Darwiche K., Boutsikou E., Machairiotis N., Tsakiridis K., Katsikogiannis N., Kougioumtzi I., Karapantzos I., Huang H., Spyratos D. Treatment of non-small cell lung cancer (NSCLC) J. Thorac. Dis. 2013;5(Suppl 4):S389–S396. - PMC - PubMed
    1. Domvri K., Zarogoulidis P., Darwiche K., Browning R.F., Li Q., Turner J.F., Kioumis I., Spyratos D., Porpodis K., Papaiwannou A., Tsiouda T., Freitag L., Zarogoulidis K. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J. Cancer. 2013;4(9):736–754. - PMC - PubMed
    1. Domvri K., Darwiche K., Zarogoulidis P., Zarogoulidis K. Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl. Lung Cancer Res. 2013;2(4):256–258. - PMC - PubMed
    1. Zarogoulidis P., Gaga M., Huang H., Darwiche K., Rapti A., Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790 where and why? Clin. Transl. Med. 2017;6(1):6. - PMC - PubMed
    1. Ricciuti B., Baglivo S., Paglialunga L., De Giglio A., Bellezza G., Chiari R., Crino L., Metro G. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther. Adv. Med. Oncol. 2017;9(6):387–404. - PMC - PubMed

Publication types